Moderna, Inc.
Biotechnology and mRNA TherapeuticsFounded 2010- Updated July 2025
Reviewed by Swet Parvadiya
Last reviewed: July 2025
CorpDigest
Moderna, Inc.
Company History
Founded 2010 in Cambridge, Massachusetts
Last reviewed: 2025-07-15 · By Swet Parvadiya
Moderna generated $1.944 billion in Total Revenue in fiscal year 2025, a 40% decrease from 2024, reflecting the collapse of COVID-19 vaccine demand from pandemic peaks to endemic seasonal levels. The company reported a GAAP net loss of $2.822 billion, with R&D expenses of $3.1 billion and operating expenses of $5.0 billion, and ended the year with approximately $6 billion in cash and investments. Moderna has three approved products, Spikevax, mNEXSPIKE, and mRESVIA, and a pipeline of more than 45 programs across respiratory vaccines, latent viruses, rare diseases, and immuno-oncology. Under CEO Stéphane Bancel, the company has reduced operating expenses by $2.2 billion in 2025, exceeding cost-reduction targets, and aims to achieve cash break-even by 2028. The company's market capitalization is approximately $18.8 billion, down from a peak of more than $180 billion in 2021. The 2026 revenue guidance projects up to 10% growth, with a 50-50 U.S.-international sales mix and continued cost discipline. The path to sustainability depends on successful launches of the flu vaccine, norovirus vaccine, and oncology products, combined with the ability to compete in seasonal vaccine markets against established pharmaceutical competitors. The company's data analytics, digital health, and patient engagement capabilities provide additional strategic options for revenue growth and market differentiation. The manufacturing quality systems and regulatory relationships support pipeline execution. The ESG commitments and patient advocacy relationships enhance stakeholder engagement. The integration of these capabilities into a cohesive commercial strategy is essential for sustainable growth. The 2026-2027 period will be critical for pipeline execution and commercial achievement.
Derrick Rossi served as a co-founder of Moderna and remained involved in the company's early scientific direction before departing to pursue other ventures. His discovery of modified mRNA reprogramming provided the initial intellectual property that attracted Flagship Pioneering's investment. Rossi later founded other biotechnology companies including Convelo Therapeutics, focused on remyelination therapies for multiple sclerosis. His scientific contributions to mRNA technology were recognized when the Karikó-Weissman foundational research, which enabled Rossi's work, was awarded the Nobel Prize in Physiology or Medicine in 2023. Rossi's role in Moderna's founding illustrates how academic breakthroughs can be translated into commercial enterprises when combined with venture capital and entrepreneurial vision. The founder's ongoing involvement with Moderna reflects a commitment to the company's mission of transforming mRNA science into medicines that improve human health.
Robert Langer has served on Moderna's board of directors since its founding and has been instrumental in guiding the company's scientific strategy and partnerships. His laboratory at MIT continues to conduct foundational research in drug delivery, tissue engineering, and nanotechnology, with more than 300 students and postdoctoral researchers trained under his supervision. Langer has received numerous awards including the National Medal of Science, the National Medal of Technology and Innovation, and the Charles Stark Draper Prize. His involvement in Moderna provided credibility with investors and scientific collaborators, and his network of academic and industry relationships facilitated partnerships that accelerated the company's development. Langer's continued board service reflects his ongoing commitment to the company's mission of transforming mRNA science into medicines. The founder's ongoing involvement with Moderna reflects a commitment to the company's mission of transforming mRNA science into medicines that improve human health.
Noubar Afeyan has served as Moderna's chairman since its founding and has been the architect of the company's strategic vision and capital structure. Under his leadership, Flagship Pioneering has built a portfolio of platform biotechnology companies that leverage scientific breakthroughs to create new therapeutic modalities. Afeyan has been instrumental in Moderna's financing strategy, including the 2018 IPO that raised $604 million and valued the company at $7.5 billion, and the subsequent capital raises that funded pandemic-scale manufacturing expansion. His vision of Moderna as a platform company rather than a product company has shaped the company's strategy of maintaining a broad pipeline across multiple therapeutic areas. Afeyan's continued involvement provides strategic continuity and access to Flagship's network of scientific and financial resources. The founder's ongoing involvement with Moderna reflects a commitment to the company's mission of transforming mRNA science into medicines that improve human health.
Kenneth Chien served as a co-founder and early scientific advisor to Moderna, contributing to the company's initial pipeline strategy in cardiovascular and rare disease therapeutics. Chien later departed from day-to-day involvement but remained a shareholder. His scientific contributions to cardiovascular biology have been recognized through numerous awards and leadership positions, including founding director of the Harvard Stem Cell Institute Cardiovascular Program. Chien's involvement in Moderna's founding illustrates how academic scientists with domain expertise can translate their research into commercial ventures when combined with platform technology and entrepreneurial leadership. His continued support for the company reflects his belief in the long-term potential of mRNA therapeutics for cardiovascular disease. The founder's ongoing involvement with Moderna reflects a commitment to the company's mission of transforming mRNA science into medicines that improve human health.
Katalin Karikó and Drew Weissman at the University of Pennsylvania publish foundational research demonstrating that modified nucleosides in mRNA can evade the body's inflammatory response, solving the key obstacle preventing mRNA therapeutics from clinical application. This discovery, later recognized with the 2023 Nobel Prize in Physiology or Medicine, provides the scientific foundation for all subsequent mRNA vaccine and therapeutic development. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Derrick Rossi, Robert Langer, Noubar Afeyan, Kenneth Chien, and Timothy Springer found Moderna Therapeutics in September 2010, with Flagship Pioneering providing seed funding and incubation. The company's name derives from modified RNA, reflecting its core technology platform. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Stéphane Bancel, former CEO of bioMérieux and executive at Eli Lilly, joins Moderna as founding CEO, bringing pharmaceutical commercial experience to the scientific founding team. Bancel's appointment signals the company's ambition to become a fully integrated pharmaceutical company rather than a technology licensor. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Moderna emerges from two years of stealth operation with a $40 million Series A financing, revealing its mRNA platform technology to the public for the first time. The company announces plans to develop mRNA therapeutics for rare diseases, cardiovascular disease, and oncology. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Moderna signs a strategic partnership with AstraZeneca worth up to $420 million to develop mRNA therapeutics for cardiovascular, metabolic, and renal diseases. The partnership validates Moderna's platform and provides non-dilutive funding for early development programs. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Moderna enters a strategic collaboration with Merck worth up to $450 million to develop personalized cancer vaccines using mRNA technology. The partnership focuses on encoding patient-specific neoantigens to stimulate anti-tumor immune responses, a approach that would later yield promising Phase 2 data. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Moderna completes its initial public offering on the Nasdaq, raising $604 million and achieving a valuation of $7.5 billion, the largest biotech IPO at the time. The IPO funds the company's pivot from rare diseases to infectious disease vaccines, reflecting the platform's speed advantage for pandemic response. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Moderna publishes Phase 1 data for its cytomegalovirus vaccine mRNA-1647 in the New England Journal of Medicine, demonstrating that mRNA vaccines could induce robust immune responses in humans. The data validates the platform's clinical viability and supports the company's expansion into larger infectious disease programs. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Moderna selects mRNA-1273 as its COVID-19 vaccine candidate on January 13, 2020, just two days after the SARS-CoV-2 sequence was published. The vaccine enters Phase 1 trial on March 16, 2020, and receives FDA Emergency Use Authorization on December 18, 2020, just 11 months after sequence selection, shattering all vaccine development records. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Moderna's COVID-19 vaccine Spikevax generates $17.7 billion in annual revenue in 2021, making it one of the best-selling pharmaceutical products in history. The company's market capitalization exceeds $180 billion, and Moderna becomes a household name globally. The vaccine is authorized in more than 70 countries. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Moderna reports $18.4 billion in revenue for 2022, a modest decline from 2021, as government advance purchase agreements transition to commercial procurement. The company begins to diversify its pipeline, announcing programs in latent viruses, rare diseases, and immuno-oncology. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Moderna's revenue falls to $6.8 billion in 2023, a 63% decline, as the COVID vaccine market transitions from pandemic to endemic demand. The company announces plans to reduce costs and diversify beyond COVID vaccines, while maintaining its manufacturing infrastructure for seasonal production. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
The FDA approves mRESVIA (mRNA-1345) for RSV prevention in adults 60 and older, marking Moderna's first non-COVID product approval. The company also reports revenue of $3.2 billion for 2024, a further 53% decline, and announces a $1.5 billion cost-reduction program. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Moderna reports $1.9 billion in revenue for 2025, a 40% decline, but reduces operating expenses by $2.2 billion, exceeding targets. The company launches mNEXSPIKE, its next-generation COVID vaccine, and expands mRESVIA to high-risk adults 18-59. The workforce is reduced by 10% to fewer than 5,000 employees. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Moderna announces that its cytomegalovirus vaccine mRNA-1647 failed to meet its Phase 3 primary endpoint in October 2025, eliminating a potential blockbuster and forcing pipeline prioritization. The failure demonstrates the risks of platform-based drug development. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
The FDA issues a Refusal-to-File letter for Moderna's seasonal flu vaccine mRNA-1010, requiring additional efficacy data before resubmission. The delay pushes potential approval into 2026 or 2027, creating uncertainty around the company's near-term revenue diversification. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Moderna acquired Carmot Therapeutics for $250 million to access CRISPR-based gene editing technology and RNA-targeted small molecule capabilities, expanding the company's platform beyond mRNA into gene editing and small molecule therapeutics. The acquisition was evaluated against alternative uses of capital and strategic priorities, with the board concluding that the technology provided competitive advantages.
Moderna acquired OriCiro Genomics for $85 million to access cell-free DNA amplification technology that improves the speed and efficiency of mRNA manufacturing, reducing production costs and increasing yields. The acquisition was evaluated against alternative uses of capital and strategic priorities, with the board concluding that the technology provided competitive advantages.